transplantation for concomitant hematologic malignancies.
1,2 Based on these observations, high-dose immunosuppression has been undertaken as therapy for patients with autoimmune diseases that are refractory to conventional immunosuppressive therapy. 3 The exact mechanism by which high-dose immunosuppression can induce remission of autoimmune diseases has yet to be determined. It is theorized that higher doses of immunosuppression may ablate the immune system, and as immune reconstitution occurs, autoreactive lymphocytes redevelop in the absence of the inciting autoantigen. 4 A higher rate of autoimmune disease relapse has been observed when unmanipulated autologous stem cells are reinfused after immunoablation when compared to allogeneic or no stem cell rescue. 5 Successful treatment of autoimmune diseases such as SLE, rheumatoid arthritis, and multiple sclerosis, have been reported after therapy with intense immunosuppression and autologous stem cell rescue. 3 To date, no cases of graft failure or prolonged cytopenias have been reported after high-dose immunosuppression and stem cell rescue. We report a patient with SLE who underwent high dose immunoablation and suffered secondary graft failure after infusion of CD34 + selected autologous stem cells.
Case report
A 32-year-old female with lupus nephritis was referred for high-dose immunosuppression therapy and stem cell rescue. The patient was diagnosed 10 years previously with systemic lupus erythematosus consisting predominantly of skin, joint and renal manifestations. Her disease flares were initially controlled with corticosteroids, but eventually required the use of higher doses of steroids, pulse cyclophosphamide, and azathioprine. 
Transplant course
The patient had a fever on day 0 and, although no infectious source was identified, treatment with broad-spectrum antibiotics was initiated (cefepime 2 g i.v. twice daily). She became neutropenic on day 1 and remained so until day 9 when her ANC recovered to 0.9 × 10 9 neutrophils/l. G-CSF was discontinued on day 10. The ANC rose to a high of 11.8 × 10 9 neutrophils/l on day 17, although the patient remained platelet and RBC transfusion dependent throughout her entire hospital course. The ANC began a precipitous decline on day 18 and remained low throughout the rest of her hospitalization ( Figure 1 ). On day 10 the patient developed fever, arthralgias, myalgias, and a diffuse erythematous rash. She was treated with broad spectrum antibiotics (piperacillin and tazobactam followed by imipenemcilastatin). Complement and ANA levels were in the normal ranges. Blood cultures were negative and she was treated presumptively for serum sickness with methylprednisolone 2 mg/kg/day. There was prompt resolution of fevers and other symptoms, the antibiotics were discontinued, and the corticosteroids were tapered. The patient remained severely neutropenic, and a bone marrow biopsy done on day 28 revealed severe aplasia with no evidence of hematopoietic recovery. Fevers developed on day 35 without evidence of infection. A broad spectrum antibiotic was administered, and her unmanipulated back-up peripheral stem cells were infused (2.84 × 10 6 CD34 + cells/kg). She remained febrile and neutropenic and required the addition of an aminoglycoside and amphotericin B to her antibiotic regimen by day 39. The presence of an autoantibody hindering engraftment was hypothesized, and apheresis with plasma exchange was performed from day 46 to 51 with no effect on peripheral blood counts. Pulmonary infiltrates developed, and on day 47 Fusarium sp. was isolated on blood culture and from bronchoalveolar washings. An HLA-identical female sibling was given G-CSF 5 g/kg s.c. daily for stem cell mobilization. The patient was prepared with one dose of ATG (40 mg/kg) on day 52, and her sister's unmanipulated stem cells were infused on day 53 (2 × 10 6 CD34 + cells/kg). The patient developed respiratory failure requiring mechanical ventilation on day 56, and later developed sepsis syndrome and multisystem organ failure. Donor granulocytes were infused on days 56 and 59. Refractory hypotension developed on day 61 and the patient expired on day 62.
Through the course of the transplant the patient showed evidence of improved renal function. Serum BUN and creatinine declined, urine output increased, and the requirement for hemodialysis was suspended from days 24 to 39. Renal function subsequently declined with the use of nephrotoxic drugs and the onset of multisystem organ failure.
Autopsy showed bone marrow aplasia with no evidence of hematopoietic recovery. However, PCR testing for donor or patient HLA type was not performed. Lung and skin cultures grew Fusarium sp., and examination of the kidney revealed changes consistent with lupus nephropathy and acute interstitial nephritis. Viral cultures were negative for hepatitis, parvovirus, EBV, and CMV.
We suspected that the patient might have an autoantibody that inhibited engraftment. We collected a sample of blood on day 27 to test the serum on a sample of her previously stored stem cells and normal control cells.
Methods
A frozen sample of the patient's previously collected stem cells and a sample from a normal donor as a control were thawed. Mononuclear cells were collected by Ficoll Hypaque density separation. 100 000 cells were plated in methyl cellulose (MethoCult H4433; Stem Cell Technologies Inc, Vancouver, BC, Canada) in the following combinations: normal donor serum with normal donor cells, normal donor serum with patient's cells, patient's serum with normal cells, and patient's serum with patient cells. All combinations were performed in triplicate. The plates were incubated at 37°C in a CO 2 incubator. On day 14 the plates were read and scored for the presence of CFU-GM, CFU-MIX, and BFU-e colonies.
Results
The results of this experiment are shown in Table 1 . The colonies grown with the patient's cells in the presence of her own serum appeared morphologically abnormal with non-adherent cells and abnormal colony shapes compared to control cells incubated in control serum (Figure 2 ). Significantly fewer BFU-e colonies grew when the patients stem cells were cultured in the presence of her serum compared to normal donor cells cultured in the patient's serum (Table 1) . Although not significant, there was a trend toward fewer CFU-GM colonies when the patient's cells were cultured in the presence of her serum than with normal serum (Table 1) .
Discussion
The preparative regimen of high-dose cyclophosphamide, ATG, and solumedrol, although myelosuppressive, should not have been myeloablative. Previous studies have shown that stem cells are resistant to killing by high-dose cyclophosphamide because of high levels of aldehyde dehydrogenase. 6 Other studies have shown that patients who received high-dose cyclophosphamide with no stem cell support have hematopoietic recovery. 7 Our patient showed sustained WBC recovery from days 9 to 18 while no longer receiving G-CSF, although she remained platelet and RBC transfusion dependent. The decline in WBC occurred just after the patient developed the fever, rash, arthralgias, and myalgias, which was diag- nosed as serum sickness and treated with high doses of corticosteroids. Clinically she improved over the next several days and the steroids were rapidly tapered, but the cytopenias persisted. We considered a differential diagnosis of transfusionassociated graft-versus-host disease, viral or medicationinduced aplasia, or immune-mediated aplasia. The patient received only irradiated and leukocyte reduced blood products making transfusion-associated GVHD unlikely. Moreover, subsequent skin biopsies revealed no pathologic changes consistent with GVHD. However molecular analysis of HLA genotypes in the peripheral blood were not accomplished. IgM antibody titers for parvovirus, hepatitis, EBV, and CMV were all negative. PCR testing for CMV viremia on peripheral blood was also negative, but no other PCR testing for viruses was performed. Although a transient decrease in blood counts is associated with acute administration of ATG and with serum sickness, complete hematopoietic aplasia is unusual. Medications such as penicillins and cephalosporins may cause immune-mediated cytopenias, but would be unlikely to cause such severe aplasia. A burst of inflammatory cytokines associated with engraftment, acute infection, or the development of serum sickness may have caused secondary loss of engraftment. Previous studies have shown that tumor necrosis factor (TNF) alpha and interferon gamma can negatively impact progenitor cell assays and engraftment. [8] [9] [10] It is also possible that relatively mature progenitors recovered primarily, but were not capable of sustaining engraftment, but this does not explain the subsequent aplasia that developed in this patient.
We hypothesized that the patient might have an autoantibody that developed after primary engraftment and may have caused secondary aplasia. Development of an antibody after such an immunosuppressive preparative regimen would be unusual, but because of the patients underlying diagnosis, rapid primary engraftment, and the experimental nature of this treatment we decided to investigate this possibility. Plasma exchange was performed without effect because plasma exchange was unable to clear the antibody, or this was not the etiology. Progenitor assays conducted with the patient's stem cells cultured with her serum collected at day 27 yielded morphologically abnormal colonies and significantly fewer BFU-e colonies than any other combination of serum and cells. This result suggests that there was something contained in the patient serum that specifically inhibited her own cell growth and maturation. Because there was no adverse effect on normal cells when incubated with patient serum, it is unlikely that the serum contained a nonspecific cell growth inhibitor such as TNF alpha or interferon gamma. The most likely explanation for the specific inhibition we observed is the presence of an autoantibody in the patient's serum that was directed against an epitope on her stem cells. Autoantibodies may have developed in response to infection, ATG administration, the manipulation of the stem cells after harvesting for CD34 selection, or spontaneously as a result of the patient's underlying autoimmune disorder. This hypothesis remains speculative because confirmatory tests for antibody in the patient's serum or on the CD34 + cells were not performed. Performing progenitor assays prior to stem cell transplantation in patients with autoimmune diseases may be helpful in delineating risks of aplasia or delayed engraftment if patient serum inhibits stem cell growth.
Although the patient's renal function improved early in her transplant course, it is unknown if this is related to the immunoablation. Previous reports of high-dose immunoablation for lupus nephritis reported improvement in renal function gradually over several months.
